我院单唾液酸四己糖神经节苷脂钠注射液的临床应用监测研究

发布时间：2018-05-07 23:40

本文选题：单唾液酸四己糖神经节苷脂钠注射液 + 临床应用　；参考：《中国药房》2017年29期

【摘要】：目的:探讨单唾液酸四己糖神经节苷脂钠注射液(GM1)致药品不良反应/药物不良事件(ADR/ADE)的一般规律、特点及相关风险因素,为临床安全、有效、经济用药提供参考。方法:通过医院局域网对2016年1-6月我院使用GM1的住院患者进行非干预集中监测,并对患者基本信息、用药情况、ADR/ADE发生情况和临床转归等进行统计分析。结果:共纳入患者621例,其中男性393例、女性228例,男女比例为1.72:1;年龄≥61岁的患者居多(60.39%)。该药主要集中应用于神经内科(71.18%)、急诊科(6.28%)、神经外科(6.12%)、全科医学科(4.67%)和中医康复科(4.03%)等5个科室。621例患者共发生ADR/ADE 28例,发生率为4.51%;超适应证用药的42例患者中发生ADR/ADE 3例,发生率为7.14%。男性ADR/ADE构成比(67.86%)高于女性(32.14%);联合用药3种及以上的有22例(78.57%);ADR/ADE主要为全身性损害(35.71%)和累及皮肤及其附件(28.57%)。579例符合适应证用药的患者中,治愈、好转、未愈的分别有165、405、9例。使用GM1的平均费用为5 108.08元,占总住院费用的9.07%,占药品总费用的23.33%。结论:加强GM1的合理用药与监测,掌握GM1致ADR/ADE的规律和特点,从而降低ADR/ADE的发生率,保障患者用药安全、有效、经济。
[Abstract]:Objective: To explore the general rules, characteristics and related risk factors of adverse drug reactions / adverse drug events (ADR/ADE) caused by Monosialotetrahexosylganglioside Sodium Injection (GM1), and to provide reference for clinical safety, effective and economical use of drugs. Methods: non intervention sets of inpatients with GM1 in our hospital in 1-6 months of 2016 were collected through the hospital LAN. The basic information, drug use, ADR/ADE occurrence and clinical outcome were analyzed. Results: 621 cases were included in the patients, including 393 men, 228 women, 228 women, 1.72:1, and 61 years old (60.39%). The drug owners should be used in Neurology (71.18%), emergency department (6.28%), and out of nerve. Department (6.12%), the General Department of Medicine (4.67%) and the 5 Department of traditional Chinese medicine (4.03%) had 5.621 cases, with a total of 28 cases of ADR/ADE, the incidence of which was 4.51%, and 3 cases of ADR/ADE in 42 patients with super adaptive drug use, the incidence of 7.14%. male ADR/ADE constituent ratio (67.86%) was higher than that of women (32.14%); there were 22 cases (78.57%) with combined medication for 3 or more; ADR/AD E is mainly for systemic damage (35.71%) and the patients involving the skin and its appendages (28.57%) in the.579 case. The cure, improvement, and no recovery are 165405,9 cases. The average cost of the use of GM1 is 5108.08 yuan, accounting for 9.07% of the total hospitalization expenses, and the 23.33%. conclusion of the total drug cost: strengthen the rational drug use and monitoring of GM1 and master the GM1. The regularity and characteristics of ADR/ADE can reduce the incidence of ADR/ADE and ensure the safety, effectiveness and economy of patients.

【作者单位】：铜仁市人民医院药学部;铜仁市食品药品监督管理局药品评价中心;
【基金】：贵州省药品评价中心科技计划项目[No.黔药监评价科研(2015)45-8]
【分类号】：R971

【相似文献】